LivaNova logo

LivaNovaNASDAQ: LIVN

Profile

Sector:

Healthcare

Country:

United Kingdom

IPO:

19 October 2015

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.72 B
-41%vs. 3y high
84%vs. sector
119.17
-88%vs. 3y high
94%vs. sector
-42%vs. 3y high
58%vs. sector
-51%vs. 3y high
41%vs. sector

Price

pre-market | 56 min ago
$50.05-$0.97(-1.90%)

Dividend

No data over the past 3 years
$318.12 M$323.64 M
$318.12 M$32.95 M

Analysts recommendations

Institutional Ownership

LIVN Latest News

LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint
zacks.com18 November 2024 Sentiment: POSITIVE

LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels.

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
businesswire.com11 November 2024 Sentiment: POSITIVE

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%
zacks.com07 November 2024 Sentiment: POSITIVE

The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript
seekingalpha.com30 October 2024 Sentiment: NEUTRAL

LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Mike Matson - Needham & Company Matt Miksic - Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2024 Earnings Conference Call. My name is Lydia, and I'll be your operator today.

LivaNova: Economics Should Start Making Sustained Improvements
seekingalpha.com18 October 2024 Sentiment: POSITIVE

LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth.

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
benzinga.com04 October 2024 Sentiment: POSITIVE

Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks.

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript
seekingalpha.com31 July 2024 Sentiment: NEUTRAL

LivaNova PLC (NASDAQ:LIVN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Ahmet Tezel – Chief Innovation Officer Conference Call Participants Rick Wise – Stifel Mike Sarcone – Jefferies Michael Polark – Wolfe Research Adam Maeder – Piper Sandler Anthony Petrone – Mizuho Group Mike Matson – Needham & Company David Rescott – Baird Matt Miksic – Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Second Quarter 2024 Earnings Conference Call. My name is Emily, and I'll be moderating your call today.

LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates
zacks.com31 July 2024 Sentiment: POSITIVE

LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
globenewswire.com26 July 2024 Sentiment: NEGATIVE

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
accesswire.com23 July 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

  • 1(current)
  • 2

What type of business is LivaNova?

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

What sector is LivaNova in?

LivaNova is in the Healthcare sector

What industry is LivaNova in?

LivaNova is in the Medical Devices industry

What country is LivaNova from?

LivaNova is headquartered in United Kingdom

When did LivaNova go public?

LivaNova initial public offering (IPO) was on 19 October 2015

What is LivaNova website?

https://www.livanova.com

Is LivaNova in the S&P 500?

No, LivaNova is not included in the S&P 500 index

Is LivaNova in the NASDAQ 100?

No, LivaNova is not included in the NASDAQ 100 index

Is LivaNova in the Dow Jones?

No, LivaNova is not included in the Dow Jones index

When was LivaNova the previous earnings report?

No data

When does LivaNova earnings report?

The next expected earnings date for LivaNova is 21 February 2025